Arax Advisory Partners
VNDA icon

Arax Advisory Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Arax Advisory Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
36,417
+34,284
+1,607% +$224K ﹤0.01% 2182
2026
Q1 		$14.7K Buy
2,133
+945
+80% +$7.29K ﹤0.01% 2251
2025
Q4 		$10.5K Sell
1,188
-15,880
-93% -$87.4K ﹤0.01% 2443
2025
Q3 		$85.2K Buy
17,068
+16,447
+2,648% +$76.1K ﹤0.01% 1594
2025
Q2 		$2.93K Buy
+621
New +$2.71K ﹤0.01% 2431
2025
Q1 		– Sell
-9
Closed -$44 – 3061
2024
Q4 		$44 Sell
9
-1,918
-100% -$9.21K ﹤0.01% 2404
2024
Q3 		$9.04K Hold
1,927
– – ﹤0.01% 1462
2024
Q2 		$10.9K Buy
+1,927
New +$9.95K ﹤0.01% 1227

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's VNDA Position: Q2 2026 in Review

Arax Advisory Partners increased its Vanda Pharmaceuticals (VNDA) stake by 1,607% in Q2 2026, buying an estimated $224K and bringing the position to 36,417 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #2182.

Arax Advisory Partners first reported a position in VNDA in Q2 2024 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Arax Advisory Partners held 36,417 shares of Vanda Pharmaceuticals worth $223K as of Q2 2026.
  • Arax Advisory Partners bought 34,284 Vanda Pharmaceuticals shares in Q2 2026, an estimated $224K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2182 holding.
  • Arax Advisory Partners first reported a position in Vanda Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.